Published in AIDS Weekly, December 19th, 2005
Researchers presented data demonstrating that the newly approved anti-HIV drug Aptivus (tipranavir) provides a convincing and lasting benefit for patients whose virus has developed resistance to other anti-HIV medications. In addition, researchers presented new safety and efficacy analyses from a head-to-head study of Viramune (nevirapine) and efavirenz, for patients with less advanced HIV.
Combined findings from two studies, RESIST-1 and RESIST-2, demonstrate that...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of AIDS Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.